1Abraham WT,Lowes BD,Ferguson DA,et al.Systemic hemodynamic,neurohormonal,and renal excretory effects of a steady-state infusion of human brain natriuretic peptide in patients with decompensated chronic heart failure.J Card Fail,1998,4:37-44.
2Mills RM,LeJemtel TH,Horton DP,et al.Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure:a randomized,double-blind,placebo-controlled clinical trial.Natrecor Study Group.J Am Coll Cardiol,1999,34:155-162.
3Colucci WS,Elkayam E,Horton DP,et al.Intravenous nesiritide,a natriuretic peptide,in the treatment of decompensated heart failure.N Engl J Med,2000,343:246-253.
4Kawakami R,Saito Y,Kishimoto I,et al.Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction.Circulation,2004,110:3306-3312.
5Keating GM,Goa KL.Nesiritide:a review of its use in acute decompensated heart failure.Drugs,2003,63:47-70.
6de Lemos JA,McGuire DK,Drazner MH.B-type natriuretic peptide in cardiovascular disease.Lancet,2003,362:316-322.
7Strain WD.The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure.Int J Clin Pract,2004,58:1081-1087.
8de Denus S,Pharand C,Williamson DR.Brain natriuretic peptide in the management of heart failure:the versatile neurohormone.Chest,2004,125:652-668.
9Colucci WS.Nesiritide for the treatment of decompensated heart failure.J Card Fail,2001,7:92-100.
